About 7,624 results
FDA Approves Botox® (Onabotulinumtoxina) For Pediatric Patients With Lower Limb Spasticity, Excluding Spasticity Caused By Cerebral Palsy

Oct 23rd, 2019 - Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX® for the treatment of pediatric patients (2 to 17 years of age) with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP). This marks the 11th BOTOX® therapeutic indication, having been approved for pedi...

WHO recommends dolutegravir as preferred HIV treatment option in all populations

Jul 21st, 2019 - Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential. Initial studies had highlighted a possible link between DTG and neural tube defects (birth defects of the brain and spinal cord that cause co...

Acupuncture for Pain
American Family Physician; Kelly, R. et. al.

Jul 14th, 2019 - Acupuncture has been increasingly used as an integrative or complementary therapy for pain. It is well-tolerated with little risk of serious adverse effects. Traditional acupuncture and nontraditional techniques, such as electroacupuncture and dry needling, often result in reported pain improvement. Multiple factors may contribute to variability in acupuncture's therapeutic effects, including n...

Arthritis Prevalence Statistics

Jun 26th, 2019 - View overall prevalence of arthritis and rheumatic diseases as well as prevalence among specific racial and ethnic groups.

Spinal Stenosis And Neurogenic Claudication - StatPearls
Munakomi, S. et. al.

Jun 3rd, 2019 - Approximately 90% of the population will present with low back pain at some point in their lifetime. Spinal stenosis is a condition that is caused by the narrowing of the central canal, the lateral recess, or neural foramen. This is a condition that can cause significant discomfort, interfere with activities of daily living, and may result in progressive disability.With increasing longevity of...

Home-Based Cardiac Rehabilitation: A Scientific Statement From the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of C...
Thomas, R. et. al.

May 11th, 2019 - Cardiac rehabilitation (CR) is an evidence-based intervention that uses patient education, health behavior modification, and exercise training to improve secondary prevention outcomes in patients with cardiovascular disease. CR programs reduce morbidity and mortality rates in adults with ischemic heart disease, heart failure, or cardiac surgery but are significantly underused, with only a minor...


May 8th, 2019 - Safety Review of DEET (chemical name, N,N-diethyl-meta-toluamide) is the active ingredient in many repellent products. It is widely used to repel biting pests such as mosquitoes and ticks. Every year, an estimated one-third of the U.S. population use DEET to protect them from mosquito-borne illnesses like West Nile Virus, the Zika virus or malaria and tick-borne illnesses like Lyme disease and ...

Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors

Apr 14th, 2019 - Cardiovascular disease is a competing cause of death in patients with cancer with early-stage disease. This elevated cardiovascular disease risk is thought to derive from both the direct effects of cancer therapies and the accumulation of risk factors such as hypertension, weight gain, cigarette smoking, and loss of cardiorespiratory fitness. Effective and viable strategies are needed to ...

International Stroke Conference 2019 Final Program

Feb 4th, 2019 - The International Stroke Conference 2019 provides unique opportunities to meet and network with colleagues from around the world with wide-ranging research interests and expertise in stroke prevention, diagnosis, treatment and rehabilitation. For 2019, we anticipate more than 4,500 professional attendees, as well as exhibitors displaying exciting new stroke products and services. We are truly d...

Risk of Posttraumatic Stress Disorder and Major Depression in Civilian Patients After Mild Traumatic Brain Injury
Stein, M. et. al.

Jan 29th, 2019 - Question Who is at greatest risk for developing mental health problems such as posttraumatic stress disorder (PTSD) or major depression after sustaining a mild traumatic brain injury (mTBI)? Findings In this cohort study of 1155 patients with mTBI and 230 patients with orthopedic injuries not involving the head, patients with mTBI were more likely to report PTSD and/or major depressive sympto...

Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative
Zeng, C. et. al.

Jan 27th, 2019 - Objective A recent randomized clinical trial reported that repeated intra-articular corticosteroids (IACs) were associated with a greater cartilage loss. This study aimed to examine the relation of IACs to knee radiographic osteoarthritis (ROA) progression in a real-world setting. Design A cohort that initiated IACs and a comparison cohort without IACs from participants with mild to moderate kn...

Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update

Sep 30th, 2018 - This systematic review is an update of an earlier report published in 2013 which evaluated questions related to stroke prevention in patients with atrial fibrillation (AF) and atrial flutter. Given evidence that has emerged since the publication of the 2013 report, this review focuses on updating and expanding the earlier work in three key areas: (1) evaluating the accuracy and utility of c...

Behavioral Therapy Approaches for the Management of Low Back Pain: An Up-To-Date Systematic Review
Pain and Therapy; Vitoula, K. et. al.

May 15th, 2018 - Low back pain is one of the most common causes for seeking medical treatment and it is estimated that one in two people will experience low back pain at some point during their lifetimes. Management of low back pain includes pharmacological and non-pharmacological approaches. Non-pharmaceutical treatments include interventions such as acupuncture, spinal manipulation, and psychotherapy. The lat...

New Treatment Guidelines for Sjögren's Syndrome

Feb 13th, 2018 - Among all the chronic autoimmune rheumatic disorders, Sjo¨ gren’s disease (SD) is among the most difficult to evaluate and manage. Clinicians are frequently challenged to differentiate symptoms related to disease activity from those that result from preexisting damage. Additionally, the presence of multiple SD-related comorbidities, including anxiety, depression and fibromyalgia,1,2 may infl...

DEET (N,N-diethyl-meta-toluamide) - ATSDR

Jan 20th, 2015 - DEET is the chemical N,N-diethyl-meta-toluamide. DEET is the active ingredient in some common repellents widely used to repel biting pests such as mosquitos and ticks. A significant benefit of DEET is protection against mosquito or tick borne illnesses such as West Nile Virus and Lyme disease. Occupational Safety and Health Administration (OSHA)

Four Strategies for Managing Opioid-Induced Side Effects in Older Adults
Rogers, E. et. al.

Apr 4th, 2014 - Opioid medications are considered key therapeutic interventions in the management of both acute pain and cancer-related pain among patients of all ages; however, their role in treating patients with chronic noncancer pain remains controversial. While the debate about the appropriate role of opioids in the treatment of chronic pain continues, the fact remains that many clinicians prescribe opioi...

Preventing Overuse Injuries | Overuse Injury Diagnosis & Prevention | STOP Sports Injuries

Mar 27th, 2010 - How to prevent sports related overuse injuries. How to spot and prevent an overuse injury.

Refractory heartburn
Gastroenterology Kahrilas, P.

May 31st, 2003 - A 33-year-old woman presents to her primary care physician with a chief complaint of heartburn for the past 12 months. She describes this as a severe burning discomfort beneath the breastbone occurring throughout the day. The patient has no history of dysphagia, vomiting, weight loss, or gastrointestinal bleeding. She reports regurgitation once a month, unchanged in the recent past. Reasoning t...

New Head Injury Data Reinforce Restricted Antipsychotic Use in Dementia

Jan 15th, 2020 - Antipsychotic medications raise the risk of head injury and traumatic brain injury (TBI) in people with Alzheimer's disease (AD), new research shows. These new data support long-standing evidence-based clinical guidance to limit the use of antipsychotics in dementia patients to those with the most severe neuropsychiatric symptoms and for as short a time as possible. "Previous studies have shown...

RimabotulinumtoxinB Reduces Sialorrhea in Adults

Jan 15th, 2020 - NEW YORK (Reuters Health) - RimabotulinumtoxinB (RIMA) safely reduces sialorrhea in adults, according to results from the phase 3 MYSTICOL clinical trial. Sialorrhea, the excess spillage of saliva from the mouth, affects up to 74% of people with Parkinson's disease and up to half of patients with amyotrophic lateral sclerosis (ALS), and it is commonly seen in stroke survivors. Injection of botu...

Electric Scooter Injuries Rising, Often Involving the Head

Jan 12th, 2020 - (Reuters Health) - Injuries and hospital admissions involving sharable two-wheeled electric scooters are on the rise in the U.S., a new study finds. Most concerning, researchers say, is that nearly a third of patients showing up at hospitals after an accident involving the powered, standing scooters had a head injury. "While most people recover from head injuries, there is going to be a subset ...

New Disability Scale Better Assesses ALS Outcomes

Jan 2nd, 2020 - NEW YORK (Reuters Health) - A new amyotrophic lateral sclerosis (ALS) disability scale (ROADS) that uses the mathematically rigorous Rasch methodology outperforms the revised ALS Functional Rating Scale (ALSFRS-R) in measuring ALS patient-reported outcomes, researchers report. "The ROADS gives the clinician practical, easy to interpret information about the patient's overall disability level, a...

Antipsychotics, dopamine, and pain

Jan 2nd, 2020 - Risperidone was the second FDA-approved SGA. Pain practitioners primarily prescribe it for treatmeant-resistant headaches, but patients with fibromyalgia and those with phantom and thalamic pain also may respond.

The FDA Recommends Only Using Cleared or Approved Medical Devices to Help Assess or Diagnose a Head Injury, Including Concussion: FDA Safety Communication | FDA

Date Issued: April 10, 2019 Audience: People who may be tested for a head injury Parents and caregivers of individuals who may be tested for a head injury Athletic Coaches and Athletic Administrators Sports medicine specialists and athletic trainers Health Care Providers who assess or diagnose head injury, including suspected concussion and other traumatic brain injuries Specialties: Primary Ca...

Stealth Bio's neuromuscular disorder drug fails trial; shares plummet

Dec 20th, 2019 - (Reuters) - Stealth BioTherapeutics Corp’s shares crashed on Friday after its lead neuromuscular disorder drug candidate failed to help patients walk better and reduce fatigue, a major setback to the company’s wide mitochondrial diseases pipeline. The drug, Elamipretide, co-developed with Alexion Pharmaceuticals, was being tested to treat primary mitochondrial myopathy (PMM). (bit.ly/35FGzTW) T...

Amylyx Drug Helps Slow ALS Progression in Mid-Stage Study

Dec 17th, 2019 - (Reuters) - Privately held drug developer Amylyx Pharmaceuticals Inc said on Tuesday its experimental therapy to treat amyotrophic lateral sclerosis (ALS) helped slow the progression of the fatal neurological disorder in a mid-stage study. ALS, also known as Lou Gehrig's disease, is a rare disorder that attacks nerve cells responsible for controlling voluntary muscles, and over 6,000 Americans ...

Amylyx drug helps slow ALS progression in mid-stage study

Dec 17th, 2019 - (Reuters) - Privately held drug developer Amylyx Pharmaceuticals Inc said on Tuesday its experimental therapy to treat amyotrophic lateral sclerosis (ALS) helped slow the progression of the fatal neurological disorder in a mid-stage study. ALS, also known as Lou Gehrig’s disease, is a rare disorder that attacks nerve cells responsible for controlling voluntary muscles, and over 6,000 Americans ...

Culture Change Needed Around Addiction Treatment in the Military

Dec 12th, 2019 - “We need to have a different answer to this because termination of opioids because a patient is positive for marijuana or even positive for cocaine doesn’t mean you take services away. You ramp services up,” Dr.

In addiction, abusive partners can wreak havoc
Randy Dotinga

Dec 9th, 2019 - SAN DIEGO – Many factors drive addiction. But clinicians often fail to address the important role played by abusive intimate partners, a psychiatrist told colleagues at the annual meeting of the American Academy of Addiction Psychiatry.

NAMDRC legislative initiatives take shape
Phil Porte, MDedge News

Dec 9th, 2019 - Two priorities of NAMDRC have moved into the formal congressional arena. The issues focus on access to pulmonary rehabilitation and CMS’s move to include home mechanical ventilation in competitive bidding.

Researchers mine free-text diary entries for seizure cluster insights
Jake Remaly

Dec 8th, 2019 - BALTIMORE – Free-text diary entries by patients with epilepsy are a “largely untapped” source of information about the frequency and treatment of seizure clusters, researchers said at the annual meeting of the American Epilepsy Society. In addition, patients may describe other clinically relevant concerns such as tiredness, depression, head injury, or seizures while driving, researchers said.

Patients With Fibromyalgia Find Relief in Group Treatment

Dec 3rd, 2019 - By the time patients get to the fibromyalgia treatment program at the Mayo Clinic in Jacksonville, Florida, they typically have tried all the approved drugs for the disorder and are tired of the pain, the fatigue, the depression, and the skepticism. "Patients tell me it's like having the flu every day," said Barbara Bruce, PhD, a behavioral psychologist who developed the program and coauthored ...

Pediatric Neurogenic Bladder Clinical Practice Guidelines (2019)

Dec 2nd, 2019 - The guidelines on management of neurogenic bladder in children and adolescents were released in November 2019 by the European Association of Urology and the European Society for Pediatric Urology.[1] In newborns with spina bifida, clean intermittent catheterization (CIC) should be started as soon as possible after birth. In those with intrauterine closure of the defect, urodynamic studies shoul...

Beyond depression: Other uses for tricyclic antidepressants

Dec 2nd, 2019 - Fibromyalgia and chronic widespread pain Fibromyalgia is a common, frustrating, noninflammatory pain syndrome characterized by diffuse hyperalgesia and multiple comorbidities. 21 Although sleep hygiene, exercise, cognitive-behavioral therapy, some gabapentinoids (pregabalin), and a combination of these therapies have demonstrated efficacy, TCAs also offer robust benefits.

Kaposi Sarcoma in a Patient With Postpolio Syndrome
Melodi Javid Whitley, MD, PhD, Willis Barrow, MD et. al.

Nov 25th, 2019 - Kaposi sarcoma (KS) is a low-grade vascular tumor that is rare among the general US population, with an incidence rate of less than 1 per 100,000. 1 The tumor is more common among certain groups of individuals due to geographic differences in the prevalence of KS-associated herpesvirus (also referred to as human herpesvirus 8) as well as host immune factors.

Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-action approval from the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS), an orphan disease.

FDA Clears Oral Film Formulation of ALS Drug Riluzole (Exservan)

Nov 24th, 2019 - The US Food and Drug Administration (FDA) has approved an oral film formulation of riluzole (Exservan, Aquestive Therapeutics) for the treatment of patients with amyotrophic lateral sclerosis (ALS), the company has announced. Exservan oral film fills a "critical need in the armamentarium for ALS patients because it can be administered safely and easily, twice daily, without water where many pat...

FDA approves Aquestive's ALS treatment

Nov 22nd, 2019 - (Reuters) - The U.S. Food and Drug Administration on Friday approved bit.ly/2pIFzi5 Aquestive Therapeutics' treatment for neurological disorder amyotrophic lateral sclerosis (ALS). Shares of the company, which developed riluzole oral film (ROF) and will market the film under the brand name Exservan, rose 4% at $6.76 after the bell. ALS is an ultra-rare neurodegenerative disorder that causes the...

Pro Soccer Players at High Risk for Death From Alzheimer's, ALS, Parkinson's

Nov 4th, 2019 - Professional soccer players appear to be at considerably increased risk for death from neurodegenerative diseases, including Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson disease (PD), new research shows. A retrospective cohort study of more than 7000 former professional soccer players showed that overall, they had a threefold increased risk for death from neurodege...

Cardiac rehab after heart valve surgery tied to better outcomes

Oct 31st, 2019 - (Reuters Health) - Cardiac rehab, known to be helpful after heart attacks, may also aid recovery from heart valve surgery, a study suggests. Older adults who got cardiac rehabilitation after heart valve surgery were less likely to be hospitalized or die over the next year than those who didn’t get this support, the study found. Researchers examined data on 41,369 people insured by Medicare, the...

Watchman: Sicker Patients, More Deaths Than in Trials

Oct 31st, 2019 - Medicare patients undergoing left atrial appendage (LAA) occlusion with the Watchman device in routine practice tended to be sicker than the trial populations, translating into higher mortality rates in the real world, researchers found. Among more than 13,000 Medicare beneficiaries with atrial fibrillation (Afib) who underwent LAA closure for stroke prevention, death and readmission rates were...

New Treatment Option Emerging for Esophagitis

Oct 30th, 2019 - SAN ANTONIO — A new option for eosinophilic esophagitis met its primary and key secondary end points in the pivotal phase 3 ORBIT study, the largest trial to date in a therapeutic area with limited treatment choices. Findings from the induction-phase trial of budesonide oral suspension (Takeda) were presented here at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting....

Secondary Syphilis Mimicking Molluscum Contagiosum in the Beard Area of an AIDS Patient
Kelly Brown, DO, Michael Koren, MD et. al.

Oct 25th, 2019 - To the Editor: A 46-year-old man with a history of AIDS (viral load, 28,186 copies/mL; CD4 count, 22 cells/μL) presented with a 40-lb weight loss over the last 6 months as well as dysphagia and a new-onset pruritic facial eruption of 1 week’s duration. The facial lesions quickly spread to involve the beard area and the upper neck.

FDA approves onabotulinumtoxinA for pediatric lower limb spasticity
Christopher Palmer

Oct 24th, 2019 - The Food and Drug Administration has approved onabotulinumtoxinA (Botox) for treatment of pediatric lower limb spasticity in patients aged 2-17 years, excluding those in whom it is associated with cerebral palsy, according to an announcement from Allergan. Olivier Le Moal/Getty Images The approval is based on a phase 3 study evaluating safety and efficacy in more than 300 patients with lower li.

Cardiac Rehab Linked to Survival Benefit After Valve Surgery

Oct 23rd, 2019 - Cardiac rehabilitation is associated with fewer deaths and hospital readmissions in the year after open heart valve surgery, although stark differences in uptake exist along racial and geographic lines, a large Medicare study shows. Cardiac rehab was associated with a relative 34% lower risk of hospitalization and 61% lower risk of mortality at 1 year. The absolute reduction in mortality was 4....

FDA Approves Botox for Lower-Limb Spasticity in Children

Oct 23rd, 2019 - The US Food and Drug Administration (FDA) has approved onabotulinumtoxinA (Botox, Allergan) to ease lower-limb spasticity in children and adolescents aged 2 years to 17 years, excluding spasticity caused by cerebral palsy (CP), the company announced. "Lower limb spasticity can impact many aspects of a child's life and have a drastic influence on their overall development and quality of life," D...

After Cardiac Valve Surgery, Too Few Go to Rehab

Oct 23rd, 2019 - Patients fresh out of cardiac valve surgery are no exception to the general underutilization of cardiac rehabilitation in the U.S., according to an observational cohort study. Enrolling in a comprehensive program of supervised exercise, cardiac risk factor modification, and psychosocial support was associated with reduced risks of re-hospitalization (adjusted HR 0.66, 95% CI 0.63-0.69) and mort...

Is carpal tunnel syndrome the tip of the iceberg?
Douglas Paauw, MD

Oct 22nd, 2019 - A 69-year-old man presents with increasing dyspnea on exertion. He has had recent orthopnea and paroxysmal nocturnal dyspnoea.

Researchers identify common reasons for misdiagnosis of ALS
Erik Greb

Oct 19th, 2019 - AUSTIN – Lack of upper motor neuron signs on examination, presence of sensory symptoms, and absence of tongue fasciculations are common causes of amyotrophic lateral sclerosis (ALS) misdiagnosis, according to an investigation presented at the annual meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine. designer491/Thinkstock Because its initial presenting symptoms.

Drug Delivers 'Remarkable' Reduction in Head Injury Deaths

Oct 15th, 2019 - Tranexamic acid (TXA) (multiple brands), an antifibrinolytic used to treat or prevent excessive blood loss, significantly reduces mortality from traumatic brain injury (TBI), results of a large, multicenter, randomized control trial show. Investigators found that administering TXA within 3 hours of head trauma was associated with a 20% reduction in deaths among those with mild to moderate TBI, ...